Showing results (131-140 of 186) with videos related to

Sort By:
Pageof 19
British Journal of Haematology|January 1, 2019
Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trialLihua E Budde, David Wu, Daniel B Martin, et al.
Blood|May 17, 2003
High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysisAjay K Gopal, Theodore A Gooley, David G Maloney, et al.
Blood|February 7, 2012
CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial resultsBrian G Till, Michael C Jensen, Jinjuan Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2013
A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine--tositumomabOliver W Press, Joseph M Unger, Lisa M Rimsza, et al.
Blood Advances|March 3, 2025
Nivolumab plus relatlimab in patients with relapsed or progressed B-cell malignancies in RELATIVITY-022Ajay K Gopal, Philippe Armand, Sattva S Neelapu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 23, 2018
Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus <sup>131</sup>I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016Mazyar Shadman, Hongli Li, Lisa Rimsza, et al.
Blood|January 2, 2014
A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemiaJohn C Byrd, John M Pagel, Farrukh T Awan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 27, 2014
Radiolabeled anti-CD45 antibody with reduced-intensity conditioning and allogeneic transplantation for younger patients with advanced acute myeloid leukemia or myelodysplastic syndromeRaya Mawad, Ted A Gooley, Joseph G Rajendran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2011
Pretargeted radioimmunotherapy using genetically engineered antibody-streptavidin fusion proteins for treatment of non-hodgkin lymphomaSteven I Park, Jaideep Shenoi, Shani M Frayo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2012
Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016Oliver W Press, Joseph M Unger, Lisa M Rimsza, et al.
Pageof 19